Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals
about
Approaches to preventative and therapeutic HIV vaccinesSafety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost RegimensAdenoviral vector-based strategies against infectious disease and cancer.Novel viral vectors in infectious diseases.Novel Concepts for HIV Vaccine Vector Design.
P2860
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Safety and Immunogenicity of a ...... e and Seropositive Individuals
@ast
Safety and Immunogenicity of a ...... e and Seropositive Individuals
@en
type
label
Safety and Immunogenicity of a ...... e and Seropositive Individuals
@ast
Safety and Immunogenicity of a ...... e and Seropositive Individuals
@en
prefLabel
Safety and Immunogenicity of a ...... e and Seropositive Individuals
@ast
Safety and Immunogenicity of a ...... e and Seropositive Individuals
@en
P2093
P2860
P50
P1476
Safety and Immunogenicity of a ...... e and Seropositive Individuals
@en
P2093
Cecilia Morgan
Edith Swann
Georgia D Tomaras
Hua-Xin Liao
Jonathan D Fuchs
Michael C Keefer
NIAID HIV Vaccine Trials Network
Nadine G Rouphael
Nicole Frahm
Nidhi Kochar
P2860
P356
10.4172/2155-6113.1000461
P50
P577
2015-05-23T00:00:00Z